Clinical trial
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD…
NCT04060199 · NS Pharma, Inc., Industry · Completed
Key facts
| NCT number | NCT04060199 |
|---|---|
| Title | Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) |
| Official title | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) |
| Lead sponsor | NS Pharma, Inc., Industry |
| Collaborators | Nippon Shinyaku Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention type | Drug |
| Interventions | Viltolarsen, Placebo |
| Enrollment | 77 |
| Start date | Apr 14, 2020 |
| Primary completion | Oct 19, 2023 |
| Completion | Oct 19, 2023 |
| First posted | Aug 19, 2019 |
| Last update posted | Dec 11, 2024 |
| Countries | Australia, Canada, Chile, China, Greece, Hong Kong, Italy, Mexico, Netherlands, New Zealand, Norway, Russia and 7 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: